Expert Interview
Discussing the commercial outlook of Coherus' Cimerli (ranibizumab biosimilar) and Outlook's Lytenava (ophthalmic formulation of bevacizumab) in Wet AMD
Ticker(s): CHRS, OTLKInstitution: UCSF
- Director of the Retina Fellowship program at the University of California San Francisco School of Medicine with over 20 years of experience as a retina surgeon and clinician scientist.
- Treats 300 patents with wet AMD
- Translational research interest includes pre-clinical development of novel technologies for ophthalmic diseases; PI on several clinical trials in wet AMD and dry AMD.
Roughly how many patients with wet AMD do you currently manage?
Added By: c_adminWhat % of your patients are on Cimerli? Lytenava?
Added By: c_adminDo you expect that the high-dose EYLEA is going to alter your early line strategies, or are you going to use it as a last resort?
Do you think the pricing for Outlook Therapeutics should be between $75 and 1300? Or, is there a certain price point that makes it attractive enough where you don't want to use a compounded product?
If you use a buy-and-bill product, do you anticipate needing support from Coherus at all?
Can you quantify how many patients are specifically on the brand name LUCENTIS? And are they having pretty good outcomes in general?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
